<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-143981</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Spanish Society for Pediatric Infectious Diseases guidelines on tuberculosis in pregnant women and neonates (i): Epidemiology and diagnosis. Congenital tuberculosis</dc:title>
<dc:description xml:lang="en">Tuberculosis (TB) screening in pregnancy using tuberculin skin test (TST) is recommended in case of symptoms of TB disease, close contact with a patient with infectious TB, or high risk of developing active disease. The new interferon gamma release assay (IGRA) tests are recommended in BCG-vaccinated pregnant women with positive TST and no known risk factors for TB, and in those immunocompromised, with clinical suspicion of TB but negative TST. TB diagnosis is difficult due to the non-specific symptoms, the increased frequency of extrapulmonary disease, the delay in radiological examinations, and the high rate of tuberculin anergy. Neonatal TB can be acquired in utero (congenital TB), or through airborne transmission after delivery (postnatal TB). Congenital TB is extremely rare and does not cause fetal malformations. It may be evident at birth, although it usually presents after the second week of life. In newborns with no family history of TB, the disease should be considered in cases of miliary pneumonia, hepatosplenomegaly with focal lesions, or lymphocytic meningitis with hypoglycorrhachia, especially in those born to immigrants from high TB-burden countries. TST is usually negative, and IGRAs have lower sensitivity than in older children. However, the yield of acid-fast smear and culture is higher, mostly in congenital TB. Molecular diagnosis techniques enable early diagnosis and detection of drug resistance mutations. There is a substantial risk of disseminated disease and death (AU)</dc:description>
<dc:creator>Mellado Peña, MJ</dc:creator>
<dc:creator>Noguera Julián, A</dc:creator>
<dc:creator>Rosal Rabes, T del</dc:creator>
<dc:creator>Calle Fernández-Miranda, M de la</dc:creator>
<dc:creator>Goncé Mellgren, A</dc:creator>
<dc:creator>Baquero-Artigao, F</dc:creator>
<dc:creator>Navarro Gómez, ML</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El cribado de tuberculosis (TB) gestacional mediante la realización de la prueba de tuberculina (PT) se recomienda a las embarazadas con síntomas compatibles, contacto íntimo con TB bacilífera o riesgo de progresión a formas activas. Las nuevas técnicas de diagnóstico interferon gamma release assay (IGRA) están indicadas en gestantes sin factores de riesgo, con PT positiva y antecedente de vacunación BCG, y en inmunodeprimidas con sospecha clínica y PT negativa. El diagnóstico de enfermedad es difícil, ya que los síntomas pueden ser inespecíficos y hay más formas extrapulmonares, por el retraso en las exploraciones radiológicas y por la mayor tasa de anergia a la tuberculina. La TB neonatal puede adquirirse de forma intrauterina (TB congénita) o por vía respiratoria tras el parto (TB posnatal). La TB congénita es excepcional, no produce malformaciones fetales y, aunque puede estar presente en el nacimiento, suele iniciarse a partir de la segunda semana de vida. En ausencia de antecedentes familiares, la TB neonatal debe sospecharse en caso de neumonía con patrón miliar, hepatoesplenomegalia con lesiones focales o meningitis linfocitaria con hipoglucorraquia, especialmente si la madre procede de áreas de alta endemia de TB. La PT es habitualmente negativa y la sensibilidad de los IGRA es inferior a la de niños de más edad. Sin embargo, la baciloscopia y el cultivo de jugo gástrico tienen una rentabilidad superior, especialmente en la TB congénita. Las técnicas de diagnóstico molecular permiten un diagnóstico precoz y la detección de mutaciones de resistencia farmacológica. El riesgo de formas diseminadas y la mortalidad son elevados (AU)</dc:description>
<dc:source>An Pediatr (Barc);83(4): 285.e1-285.e8, oct. 2015. tab, ilus</dc:source>
<dc:identifier>ibc-143981</dc:identifier>
<dc:title xml:lang="es">Guía de la Sociedad Española de Infectología Pediátrica sobre tuberculosis en la embarazada y el recién nacido (I): epidemiología y diagnóstico. Tuberculosis congénita</dc:title>
<dc:subject>^d14778^s22013</dc:subject>
<dc:subject>^d25123^s22045</dc:subject>
<dc:subject>^d14778^s22054</dc:subject>
<dc:subject>^d19062</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d54661^s22045</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d13339^s22048</dc:subject>
<dc:subject>^d14778^s22016</dc:subject>
<dc:subject>^d22710^s22045</dc:subject>
<dc:subject>^d22261</dc:subject>
<dc:subject>^d22710^s22039</dc:subject>
<dc:subject>^d29636</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d14778^s22080</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d54661^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d23481^s22074</dc:subject>
<dc:subject>^d13339^s22074</dc:subject>
<dc:subject>^d54661^s22039</dc:subject>
<dc:subject>^d22226</dc:subject>
<dc:subject>^d22710^s22074</dc:subject>
<dc:subject>^d13568^s22046</dc:subject>
<dc:type>article</dc:type>
<dc:date>201510</dc:date>
</metadata>
</record>
</ibecs-document>
